GreenLight Biosciences- Warrants (30/09/2027) EBIT

The latest EBIT for GRNAW is $-160M as of March 2023. That compares with $-29M in the prior-year period — down 438.2% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside GreenLight Biosciences- Warrants (30/09/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, GRNAW's EBIT moved from $-29M to $-160M — a 438.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GreenLight Biosciences- Warrants (30/09/2027)'s operating scale or balance-sheet position.

Against its sector companies, GRNAW currently prints $-160M for EBIT, while the sector average sits near $-6.4M. That is roughly 2327.8% below the sector mean. Large gaps often invite a closer look at GreenLight Biosciences- Warrants (30/09/2027)'s growth, margins, and balance sheet.

A EBIT figure of $-160M for GRNAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting GRNAW's EBIT ($-160M), review year-over-year change from $-29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.